High glutamine increases stroke risk by inducing the endothelial‐to‐mesenchymal transition in moyamoya disease

• Published in: MedComm (2020) Vol. 5; no. 5; pp. e525 - n/a
• Main Authors: He, Qiheng, Li, Junsheng, Tao, Chuming, Zeng, Chaofan, Liu, Chenglong, Zheng, Zhiyao, Mou, Siqi, Liu, Wei, Zhang, Bojian, Yu, Xiaofan, Zhai, Yuanren, Wang, Jia, Zhang, Qian, Zhang, Yan, Zhang, Dong, Zhao, Jizong, Ge, Peicong
• Format: Journal Article
• Language: English
• Published: China John Wiley & Sons, Inc 01.05.2024; John Wiley and Sons Inc; Wiley
• Subjects: endothelial‐to‐mesenchymal transition; glutamine; Integrin Subunit Beta 4; moyamoya; Original; Smad; stroke; endothelial‐to‐mesenchymal transition; Smad; glutamine; moyamoya; stroke; Integrin Subunit Beta 4
• ISSN: 2688-2663; 2688-2663
• DOI: 10.1002/mco2.525

At present, there is limited research on the mechanisms underlying moyamoya disease (MMD). Herein, we aimed to determine the role of glutamine in MMD pathogenesis, and 360 adult patients were prospectively enrolled. Human brain microvascular endothelial cells (HBMECs) were subjected to Integrin Subunit Beta 4 (ITGB4) overexpression or knockdown and atorvastatin. We assessed factors associated with various signaling pathways in the context of the endothelial‐to‐mesenchymal transition (EndMT), and the expression level of related proteins was validated in the superficial temporal arteries of patients. We found glutamine levels were positively associated with a greater risk of stroke (OR = 1.599, p = 0.022). After treatment with glutamine, HBMECs exhibited enhanced proliferation, migration, and EndMT, all reversed by ITGB4 knockdown. In ITGB4‐transfected HBMECs, the MAPK–ERK–TGF–β/BMP pathway was activated, with Smad4 knockdown reversing the EndMT. Furthermore, atorvastatin suppressed the EndMT by inhibiting Smad1/5 phosphorylation and promoting Smad4 ubiquitination in ITGB4‐transfected HBMECs. We also found the protein level of ITGB4 was upregulated in the superficial temporal arteries of patients with MMD. In conclusion, our study suggests that glutamine may be an independent risk factor for hemorrhage or infarction in patients with MMD and targeting ITGB4 could potentially be therapeutic approaches for MMD. Glutamine levels were positively associated with a greater risk of stroke (OR = 1.599, p = 0.022). After treatment with glutamine, HBMECs exhibited enhanced proliferation, migration, and EndMT, all reversed by ITGB4 knockdown. In ITGB4‐transfected HBMECs, the MAPK–ERK–TGF–β/BMP pathway was activated, with Smad4 knockdown reversing the EndMT. Furthermore, atorvastatin suppressed the EndMT by inhibiting Smad1/5 phosphorylation and promoting Smad4 ubiquitination in ITGB4‐transfected HBMECs. Finally, ITGB4 upregulation was confirmed in the superficial temporal arteries of patients with MMD.